MEDIAN TECHNOLOGIES (EGFF)

The project will finance Research & Development (R&D) investments made by Median Technologies, a French commercial-stage medtech company operating in the field of medical imaging in France and internationally. The EIB loan will contribute to finance (i) the recruitment of Artificial Intelligence experts, (ii) the creation of a proprietary data-base of patient history (iii) the clinical validation and regulatory approval of the software and algorithms and (iv) prepare the market access for the new business line.

With its new software, Median aims to offer radiologists a tool to help them with the interpretation of clinical images using the latest artificial intelligence techniques and deep learning technologies.

The project would not require an Environmental Impact Assessment (EIA) under Directive 2014/52/EU amending the Directive 2011/92/EC as R&D investments will be carried out in facilities already authorised for the same purpose. Full environmental details will nevertheless verified during the appraisal, to align with EU best practices.

Median has been assessed by the EIB as a private company not subject to EU rules on public procurement or concessions. However, if after the project appraisal, the EIB were to conclude that the company is subject to EU public procurement legislation 2014/24/EU where applicable, it will require Median to ensure that contracts for the implementation of the project will be tendered in accordance with the relevant applicable EU procurement legislation Directive 2014/24/EU, where applicable, as well as Directive 89/665/EEC as interpreted by the Court of Justice of the EU, with publication of tender notices in the EU Official Journal, as and where required.